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Abstract
Background: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer.
Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in
plasma and breast cancer risk.
Methods: A nested case-control study was established within the European Prospective Investigation into
Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known
estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127,
acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by
mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer
incidence using multivariable conditional logistic regression.
Results: Among women not using hormones at baseline (n= 2248), and after control for multiple tests, concentrations of
arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and
phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)),
ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while
the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR =
1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships
did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity.
Conclusions: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results
warrant replication in other epidemiological studies.
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Background
Breast cancer is the most common cancer among
women worldwide [1]. Known modifiable hormonal and
lifestyle risk factors, however, are estimated to be re-
sponsible for only around 30% of breast cancers in high-
income countries [2–8], so a better understanding of the
etiology of the disease and of the biological mechanisms
is needed.
The metabolome reflects endogenous processes and en-
vironmental and lifestyle factors [9–13]. Metabolomics can
detect subtle differences in metabolism; therefore, it is a
promising tool to identify new etiological pathways. Previ-
ous prospective studies of breast cancer which have
employed metabolomics have used both targeted (analyses
of a pre-defined panel of metabolites) [14] or untargeted
(where as many metabolites as possible are measured and
then characterized [15]) approaches [16–18]. In previous
studies, lysophosphatidylcholine a C18:0 [14], various lipids,
acetone, and glycerol-derived compounds [16], 16a-
hydroxy-DHEA-3-sulfate, 3-methylglutarylcarnitine [17],
and caprate (10:0), were associated with breast cancer de-
velopment [18]. The number of cases included in these
studies was, however, limited (from 200 to 621) and hetero-
geneity by subtype was investigated in only one study [18].
In the current study, we employed a targeted metabo-
lomics approach to prospectively investigate the associa-
tions between 127 metabolites measured by mass
spectrometry in pre-diagnostic plasma samples and risk
of breast cancer, overall, and by breast cancer subtype,
accounting for established breast cancer risk factors.
Methods
Study population, blood collection, and follow-up
EPIC is an ongoing multi-center cohort study including
approximately 520,000 participants recruited between
1992 and 2000 from ten European countries [19].
Female participants (n = 367,903) were aged 35–75 years
old at inclusion. At recruitment, detailed information
was collected on dietary, lifestyle, reproductive, medical,
and anthropometric data [19]. Around 246,000 women
from all countries provided a baseline blood sample.
Blood was collected according to a standardized protocol
in France, Germany, Greece, Italy, the Netherlands,
Norway, Spain, and the UK [19]. Serum (except in
Norway), plasma, erythrocytes, and buffy coat aliquots
were stored in liquid nitrogen (− 196 °C) in a centralized
biobank at IARC. In Denmark, blood fractions were
stored locally in the vapor phase of liquid nitrogen con-
tainers (− 150 °C), and in Sweden, they were stored lo-
cally at − 80 °C in standard freezers.
Incident cancer cases were identified through record
linkage with cancer registries in most countries and
through health insurance records, cancer and pathology
registries, and active follow-up of study subjects in
France, Germany, and Greece. For each EPIC center,
closure dates of the study period were defined as the
latest dates of complete follow-up for both cancer inci-
dence and vital status (dates varied between centers,
from June 2008 to December 2012).
All participants provided written informed consent to
participate in the EPIC study. This study was approved
by the ethics committee of the International Agency for
Research on Cancer (IARC) and all centers.
Selection of cases and controls
Subjects were selected among participants who were
cancer-free (other than non-melanoma skin cancer) and
had donated blood at recruitment into the cohort. Cancers
were coded according to the Third Edition of the Inter-
national Classification of Diseases for Oncology (code
C50). Women diagnosed with first primary invasive breast
cancer at least 2 years after blood collection and before
December 2012, for whom estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth factor
receptor 2 (HER2) statuses of the tumors were available,
were selected as cases for the current study.
For each breast cancer case, one control was chosen at
random among appropriate risk sets comprising all fe-
male cohort members who were alive and without can-
cer diagnosis (except non-melanoma skin cancer) at the
time of diagnosis of the index case. Using incidence
density sampling, controls were matched to cases on
center of recruitment, age (± 6 months), menopausal sta-
tus (premenopausal, perimenopausal, postmenopausal,
surgically postmenopausal [20]), phase of the menstrual
cycle [20], use of exogenous hormone at blood collec-
tion, time of the day (± 1 h), and fasting status at blood
collection (non-fasting (< 3 h since last meal), in between
(3–6 h), fasting (> 6 h), unknown).
Initially, 1626 cases and 1626 controls were eligible for
the study, but after the exclusion of pregnant women at
blood collection, a final population of 1624 cases and
1624 controls were included in the analysis.
Laboratory measurements
All plasma samples were assayed in the Biomarkers la-
boratory at IARC, using the AbsoluteIDQ p180 platform
(Biocrates Life Sciences AG, Innsbruck, Austria) and
following the procedure recommended by the vendor. A
QTRAP5500 mass spectrometer (AB Sciex, Framingham,
MA, USA) was used to measure 147 metabolites (19
acylcarnitines, 21 amino acids, 13 biogenic amines, 79
glycerophospholipids, 14 sphingolipids and hexoses).
Samples from matched case-control sets were assayed in
the same analytical batch. Laboratory personnel were
blinded to case-control status of the samples.
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Selection of metabolites
Metabolites were analyzed in samples from 3247 distinct
subjects (one subject included in 2 pairs). Completeness
of measures and coefficients of variation (median = 5.3%,
interquartile range = 1.4%) are shown in Additional file 1:
Table S1. Values lower than the lower limit of quantifi-
cation (LLOQ), or higher than the upper limit of quanti-
fication (ULOQ), as well as lower than batch-specific
limit of detection (LOD) (for compounds measured with
a semi-quantitative method: acylcarnitines, glyceropho-
spholipids, sphingolipids), were considered out of the
measurable range. Metabolites were excluded from the
statistical analyses if more than 20% of observations
were outside the measurable range (n = 20). A total of
127 metabolites (8 acylcarnitines, 20 amino acids, 6 bio-
genic amines, 78 glycerophospholipids, 14 sphingolipids
and hexoses) were finally retained for statistical analyses.
Of these 127 metabolites, 113 had all values included in
the measurable range. For the remaining 14 metabolites,
values outside the quantifiable range (all lower than
LLOQ or LOD) were imputed with half the LLOQ or
half the batch-specific LOD, respectively.
Statistical analysis
Characteristics of cases and controls were described
using mean and standard deviation (SD) or frequency.
Geometric means were used to describe non log-
transformed metabolite concentrations among cases
and controls. Log-transformed metabolite concentra-
tions were used in all other analyses. Partial Pearson’s
correlations between metabolites, adjusted for age at
blood collection, were estimated among controls.
We used conditional logistic regression to estimate the
risk of breast cancer per standard deviation (SD) in-
crease in metabolite concentration. The analysis was
conditioned on the matching variables. Likelihood ratio
tests were performed to compare linear models with
cubic polynomial models in order to assess departure
from linearity. Multiple testing was addressed by con-
trolling for family-wise error rate at α = 0.05 by
permutation-based stepdown minP adjustment of P
values, as this method better accounts for the depend-
ence of the tests [21, 22]. For comparison with previous
studies, we also adjusted the raw P values using Bonfer-
roni correction (P < 0.05/127) and controlling for the
false discovery rate (FDR) at α = 0.05 [23]. All statistical
tests were two-sided.
Metabolites showing a statistically significant associ-
ation with risk of breast cancer after correcting for
multiple testing were categorized into quintiles based
on the distribution of the concentrations among con-
trols, and odds ratios (OR) for risk of breast cancer
were estimated in each category. For tests of linear
trend, participants were assigned the median value in
each quintile and we modeled the corresponding
variable as a continuous term. To identify potential
confounders, models of the metabolites of interest
(continuous and quintiles) were adjusted separately
for each potential confounder and estimates obtained
were compared with estimates from models with
matching variables only. Only variables that changed
parameter estimates by more than 10% were retained
in the multivariable model. Variables tested were as
follows: age at first menstrual period (continuous),
number of full-term pregnancies (0/1/2/≥ 3), age at
first full-term pregnancy (never pregnant/quartiles),
breastfeeding (ever/never/never pregnant/missing; dur-
ation in quintiles), ever use of oral contraceptive (yes/
no), ever use of MHT (yes/no/missing), smoking
status (never/former/current), level of physical activity
(Cambridge index [24]: inactive/moderately inactive/
moderately active/active), alcohol consumption (non-
drinkers/> 0–3/3–12/12–24 g/day), education level (no
schooling or primary/technical, professional or sec-
ondary/longer education), energy intake (continuous,
quintiles), height (continuous, quintiles), sitting height
(missing/quartiles), weight (continuous, quintiles),
body mass index (continuous, quintiles), waist circum-
ference (continuous, quintiles), hip circumference
(continuous, quintiles), and hypertension (yes/no). For
these variables, missing values were assigned the me-
dian (continuous variables) or mode (categorical vari-
ables) if they represented less than 5% of the
population, or were otherwise classified in a “missing”
category (breastfeeding, ever use of MHT, sitting
height). Only waist circumference (continuous), hip
circumference (continuous), and weight (continuous)
were included in the final models. Given the correla-
tions between these variables (> 0.77), these variables
were included separately in three different models.
For those metabolites showing a significant association
with breast cancer risk after controlling for multiple test-
ing, heterogeneity was investigated by menopausal status
at blood collection, use of exogenous hormones at blood
collection, fasting status at blood collection, age at diag-
nosis (age 50 or older/younger than age 50), breast can-
cer subtype (ER+PR+/−HER2+, ER+PR+/−HER2−, ER
−PR−HER2+, ER−PR−HER2−), time between blood col-
lection diagnosis (2–8.6 years/more than 8.6 years), and
at recruitment waist circumference (WC) (< 80 cm/≥80
cm), BMI (< 25 kg/m2/≥25 kg/m2), and country, by intro-
ducing interaction terms in the models. Subgroup ana-
lyses were conducted on the raw models. For WC,
unconditional logistic regression adjusted for each
matching factor was used. P values were not corrected
for multiple tests since heterogeneity was investigated
only for metabolites showing statistically significant
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Table 1 Main characteristics of the study population
Variables N Controls Cases
N = 1624 N = 1624
Mean (SD) or N (%) Mean (SD) or N (%)
Age at blood collection (years) 3248 52.5 (7.9) 52.5 (8.0)
Length of follow-up from blood collection (years) 3248 – 8.3 (2.8)
Age at diagnosis (years) 1624 – 60.8 (8.3)
ER status 1624
Negative – 313 (19.3)
Positive – 1311 (80.7)
PR status 1624
Negative – 516 (31.8)
Positive – 1108 (68.2)
HER2 status 1624
Negative – 1270 (78.2)
Positive – 354 (21.8)
Age at first menstrual period (years) 3248 13.1 (1.6) 13.0 (1.5)
Number of full-term pregnancies 3248
0 215 (13.2) 244 (15.0)
1 253 (15.6) 310 (19.1)
2 729 (44.9) 686 (42.2)
≥ 3 427 (26.3) 384 (23.6)
Age at first full-term pregnancy (years) 2789 24.9 (4.3) 25.3 (4.4)
Ever breastfed 3248
No 194 (11.9) 206 (12.7)
Yes 1116 (68.7) 1080 (66.5)
Never pregnant 215 (13.2) 244 (15.0)
Missing 99 (6.1) 94 (5.8)
Use of exogenous hormones at blood collection 3248
No 1124 (69.2) 1130 (69.6)
Yes 492 (30.3) 494 (30.4)
Missing 8 (0.5) 0 (0.0)
Menopausal status at blood collection 3248
Premenopausal 434 (26.7) 434 (26.7)
Postmenopausal 869 (53.5) 872 (53.7)
Perimenopausal 321 (19.8) 318 (19.6)
Fasting status at blood collection (time since last meal) 3248
< 3 h 737 (45.4) 731 (45.0)
3–6 h 284 (17.5) 285 (17.5)
> 6 h 580 (35.7) 580 (35.7)
Unknown 23 (1.4) 28 (1.7)
Alcohol consumption at recruitment (g/day) 3248 8.9 (12.2) 10.2 (13.5)
Education level 3248
Primary/no schooling 610 (37.6) 597 (36.8)
Technical/professional/secondary 687 (42.3) 688 (42.4)
Longer education 327 (20.1) 339 (20.9)
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associations with risk overall, after correction for mul-
tiple testing.
A sensitivity analysis of all 127 metabolites was per-
formed on hormone non-users (1124 cases and 1124
controls) and by cancer subtype.
Analyses were conducted using SAS software for Win-
dows (version 9.4, Copyright© 2017, SAS Institute Inc.)
and R software (packages Epi and NPC) [25, 26].
Results
Cases were diagnosed on average 8.3 years after blood
collection, at a mean age of 60.8 years. The majority of
tumors were ER-positive (80.7%), PR-positive (68.2%),
and HER2-negative (78.2%) (Table 1). Mean concentra-
tions of metabolites by case/control status are shown in
Additional file 1: Table S2.
Overall, positive, moderate correlations were observed
among some of the amino acids, phosphatidylcholines
(PCs), lysoPCs, and sphingomyelins (see Additional file 1:
Figure S1); the average absolute correlations within each
class was 0.36, 0.39, 0.45, and 0.55, respectively (data not
tabulated).
Associations of metabolites with breast cancer risk
Prior to correction for multiple testing, 29 metabolites
were significantly associated with the risk of breast can-
cer with a raw P value lower than 0.05 (Fig. 1a and
Table 2), mainly amino acids, PCs (inversely associated),
and acylcarnitines (directly associated). However, after
adjusting for multiple testing (Fig. 1b), only C2 (OR for
1 SD increment = 1.15, 95% CI = 1.06–1.24, corrected P
value = 0.031) and phosphatidylcholine PC ae C36:3 (OR
for 1 SD increment = 0.88, 95% CI = 0.82–0.95, corrected
P value = 0.044) remained significantly associated with
risk of breast cancer (Table 2). Adjustment for multiple
testing using FDR procedure identified similar significant
metabolites, while with Bonferroni correction, only C2
remained associated with risk of breast cancer with a
borderline significant P value (Bonferroni P value =
0.051) (Table 2). Departure from linearity was suggested
for glutamate, C0, kynurerine, and SDMA. However,
when non-linear models were examined, and after con-
trolling for multiple tests, no non-linear association
remained significant (results not shown).
When C2 and PC ae C36:3 were further analyzed as
categorical variables, results similar to those of the linear
analysis were obtained; logistic regression conditioned
on the matching variables showed a linear trend across
quintiles of C2 (OR quintile 5 versus quintile 1 = 1.54,
95% CI = 1.21–1.95, P trend = 0.0002) and of PC ae C36:
3 (OR quintile 5 versus quintile 1 = 0.73, 95% CI = 0.58–
0.91, P trend = 0.0003) (Table 3). Adjusting for an-
thropometric variables in separate models had little ef-
fect on the risk estimates (Table 3).
Stratification by hormone therapy
Statistically significant heterogeneity was observed by
use of hormones at blood collection for the associations
of C2 (P homogeneity = 0.035) and PC ae C36:3 (P
homogeneity = 0.017) with breast cancer, with statisti-
cally significant associations restricted to hormone non-
users (C2: OR per SD = 1.23, 95% CI = 1.11–1.35; PC ae
C36:3: OR per SD = 0.83, 95% CI = 0.76–0.90) and no as-
sociations observed in users (C2: OR per SD = 1.03, 95%
Table 1 Main characteristics of the study population (Continued)
Variables N Controls Cases
N = 1624 N = 1624
Mean (SD) or N (%) Mean (SD) or N (%)
Height (cm) 3248 161.4 (6.6) 162.0 (6.6)
Weight (kg)
Age at diagnosis < 50 years old 382 63.8 (11.3) 63.0 (10.9)
Age at diagnosis ≥ 50 years old 2866 66.7 (10.8) 68.4 (12.2)
Body mass index (kg/m2)
Age at diagnosis < 50 years old 382 24.2 (4.1) 23.9 (4.2)
Age at diagnosis ≥ 50 years old 2866 25.7 (4.1) 26.1 (4.6)
Waist circumference (cm)
Age at diagnosis < 50 years old 382 76.8 (9.8) 76.4 (10.3)
Age at diagnosis ≥ 50 years old 2866 81.0 (10.4) 82.5 (11.3)
Hip circumference (cm)
Age at diagnosis < 50 years old 382 99.0 (8.6) 98.3 (8.4)
Age at diagnosis ≥ 50 years old 2866 101.4 (8.0) 102.7 (9.1)
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor
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CI = 0.91–1.17; PC ae C36:3: OR per SD = 1.00, 95% CI =
0.88–1.13; Fig. 2).
In an analysis of the 127 metabolites restricted to hor-
mone non-users (n = 2248) (Fig. 3), we identified additional
metabolites showing statistically significant inverse associa-
tions with risk of breast cancer after adjustment of P values
for multiple testing, for which heterogeneity was also inves-
tigated. These metabolites were as follows: arginine (OR
per SD = 0.79, 95% CI = 0.70–0.90; P homogeneity = 0.002),
asparagine (OR per SD = 0.83, 95% CI = 0.74–0.92; P
homogeneity = 0.12), PC aa C36:3 (OR per SD = 0.84, 95%
CI = 0.77–0.93; P homogeneity = 0.12), PC ae C34:2 (OR
per SD = 0.85, 95% CI = 0.78–0.94; P homogeneity = 0.04),
PC ae C36:2 (OR per SD = 0.85, 95% CI = 0.78–0.88; P
homogeneity = 0.04), and PC ae C38:2 (OR per SD = 0.84,
95% CI = 0.0.76–0.93; P homogeneity = 0.10).
No significant heterogeneity was observed for the asso-
ciation of C2 and PC ae C36:3 with breast cancer by
Fig. 1 Odds ratios (ORs) for the associations between metabolites and breast cancer. a Raw P values. b Adjusted P values. PC:
phosphatidylcholine; SM: sphingomyelin. ORs are estimated per standard deviation (SD) increase in log-transformed metabolite concentrations,
from logistic regression conditioned on matching variables. a Statistical significance based on raw P values (significant metabolites above dotted
line). b Statistical significance based on P values adjusted by permutation-based stepdown minP (see “Methods” section for details); adjusted P
values above 0.05 (dotted line) were considered statistically significant after correction for multiple tests
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menopausal status, fasting status at blood collection,
breast cancer subtype, age at diagnosis, WC (P homo-
geneity all > 0.12, Fig. 2), country (P homogeneity of 0.50
for C2 and 0.12 for PC ae C36:3) or by time between
blood collection and diagnosis (2–8.6/≥8.6 years (me-
dian); P homogeneity of 0.17 for C2 and 0.98 for PC ae
C36:3) (data not shown).
Stratification by breast cancer subtypes for all metabo-
lites (see Additional file 1: Figure S2) showed that no
metabolite reached statistical significance after correc-
tion for multiple testing in each subtype, although for
ER+PR+/−HER2− cases (n = 1084 cases), PC ae C36:3
and PC aa C36:3 had adjusted P values close to statistical
significance (0.066 and 0.074, respectively).
Table 2 Associations between metabolites (continuous) and risk of breast cancer, for metabolites with raw P values < 0.05
Class Metabolite Odds ratio and 95% CI (for
1 SD)a
Raw P
value
Permutation-based minP P
valueb
Bonferroni P
valuec
False discovery rate P
valued
Amino acids Arginine 0.89 (0.80–0.99) 0.035 0.753 1.000 0.166
Asparagine 0.87 (0.80–0.95) 0.002 0.109 0.240 0.062
Glutamine 0.91 (0.84–0.99) 0.031 0.731 1.000 0.166
Glycine 0.90 (0.83–0.97) 0.005 0.229 0.629 0.090
Histidine 0.91 (0.84–0.99) 0.020 0.588 1.000 0.131
Lysine 0.90 (0.83–0.98) 0.010 0.389 1.000 0.102
Threonine 0.92 (0.85–0.99) 0.034 0.752 1.000 0.166
Acylcarnitines C14:1 1.09 (1.01–1.18) 0.028 0.704 1.000 0.166
C18:1 1.11 (1.00–1.22) 0.040 0.793 1.000 0.183
C2 1.15 (1.06–1.24) 0.0004 0.031 0.051 0.036
Glycerophospholipids PC aa C32:3 0.90 (0.82–0.99) 0.026 0.674 1.000 0.166
PC aa C36:2 0.89 (0.82–0.97) 0.009 0.339 1.000 0.099
PC aa C36:3 0.89 (0.82–0.96) 0.002 0.117 0.272 0.062
PC aa C38:3 0.92 (0.85–0.99) 0.035 0.753 1.000 0.166
PC ae C34:2 0.90 (0.84–0.97) 0.008 0.317 0.966 0.099
PC ae C36:2 0.90 (0.84–0.98) 0.009 0.339 1.000 0.099
PC ae C36:3 0.88 (0.82–0.95) 0.001 0.044 0.073 0.036
PC ae C38:2 0.88 (0.81–0.96) 0.002 0.128 0.310 0.062
PC ae C38:3 0.90 (0.83–0.98) 0.012 0.425 1.000 0.107
PC ae C38:5 0.93 (0.86–1.00) 0.047 0.836 1.000 0.205
PC ae C40:1 0.92 (0.84–0.99) 0.030 0.730 1.000 0.166
PC ae C40:4 0.91 (0.84–0.98) 0.018 0.553 1.000 0.129
PC ae C42:1 0.90 (0.83–0.98) 0.010 0.393 1.000 0.102
lysoPC a
C18:0
0.88 (0.80–0.98) 0.014 0.473 1.000 0.115
lysoPC a
C18:2
0.89 (0.81–0.96) 0.004 0.209 0.559 0.090
lysoPC a
C20:3
0.90 (0.83–0.98) 0.013 0.434 1.000 0.107
Sphingolipids SM C20:2 0.90 (0.82–0.98) 0.018 0.546 1.000 0.129
SM (OH)
C22:1
0.90 (0.83–0.97) 0.008 0.322 1.000 0.099
Sugars Hexose 1.12 (1.01–1.24) 0.035 0.752 1.000 0.166
SD standard deviation, CI confidence interval
Italicized text indicates a statistically significant association with breast cancer risk after adjustment of P values by permutation-based minP
aOdds ratios were estimated by logistic regression conditioned on center of recruitment, age, menopausal status at the time of blood collection, phase of the
menstrual cycle at blood collection (for premenopausal women only), use of exogenous hormone at blood collection, time of the day at blood collection, and
fasting status at blood collection
bMultiple testing controlled for family-wise error rate at α = 0.05 by permutation-based stepdown minP adjustment of P values
cMultiple testing controlled for family-wise error rate at α = 0.05 by Bonferroni adjustment of P values
dMultiple testing controlled for false discovery rate at α = 0.05
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Discussion
In this prospective analysis that investigated the asso-
ciation of 127 circulating metabolites with breast can-
cer incidence, among women not using hormones at
baseline, and after control for multiple tests, acylcar-
nitine C2 was positively associated with risk of breast
cancer, while levels of a set of phosphatidylcholines
(ae C36:3, aa C36:3, ae C34:2, ae C36:2 and ae C38:2)
and the amino acids arginine and asparagine were in-
versely associated with disease risk. In the overall
population (hormone users and non-users), only C2
and PC ae C36:3 were associated with risk of breast
cancer independently from breast cancer subtype, age
at diagnosis, fasting and menopausal status at collec-
tion, or adiposity.
Acylcarnitine C2 plays a key role in the transport of fatty
acids into the mitochondria for β-oxidation [27, 28]. In
human intervention studies, plasma concentration levels
have been seen to vary according to the activity of the fatty
oxidation pathway [28, 29]. High C2 levels are associated
to other known mechanisms involved in breast cancer de-
velopment, such as hyperinsulinemia and insulin resist-
ance [30], consistent with some studies showing increased
plasma concentrations of acetylcarnitine in pre-diabetic or
diabetic women [31–33]. An explanation for the associa-
tions observed only in women not using hormones, for C2
and for other metabolites, could be that due to their in-
creased exposure to estrogens, MHT users are already at a
higher risk of breast cancer than non-users [34], similarly
to what is observed for BMI and postmenopausal breast
cancer risk [35].
Phospholipids are a major component of cell mem-
branes and play a major role in cell signaling and cell
cycle regulation. Previous studies of phospholipids
showed that PC ae C36:3 concentrations were decreased
in type 2 diabetes [36, 37] and that lower serum levels
were predictive of future diabetes [38]. Lower concentra-
tions of PCs ae C38:2 and ae C34:2 were also observed
in diabetic men compared to non-diabetics [37]. A bio-
logical basis for such inverse associations could rely on
observed antioxidant effect of PCs [39].
In line with the inverse association observed between
arginine and risk of breast cancer in hormone non-users,
decreased plasma concentrations of arginine has been
observed in breast cancer patients [40] compared with
controls. Both human [41] and animal [42] studies have
Table 3 Associations between C2 and PC ae C 36:3 and risk of breast cancer
Cases/
controls
Model 1c Model 2—adjusted for WC Model 3—adjusted for weight Model 4—adjusted for HC
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
C2
Per SD increment 1624/1624 1.15 (1.06–1.24) 1.14 (1.06–1.23) 1.15 (1.06–1.24) 1.14 (1.06–1.24)
C2 (quintiles)a
1 287/322 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
2 291/326 1.02 (0.81–1.28) 1.00 (0.79–1.26) 1.00 (0.80–1.27) 1.00 (0.80–1.26)
3 322/324 1.15 (0.91–1.44) 1.12 (0.89–1.41) 1.13 (0.90–1.42) 1.13 (0.89–1.42)
4 311/326 1.12 (0.89–1.41) 1.09 (0.87–1.37) 1.09 (0.87–1.37) 1.10 (0.87–1.38)
5 413/326 1.54 (1.21–1.95) 1.51 (1.19–1.91) 1.53 (1.20–1.93) 1.52 (1.20–1.93)
P trendb 0.0002 0.0005 0.0004 0.0004
PC ae C36:3
Per SD increment 1624/1624 0.88 (0.82–0.95) 0.90 (0.83–0.97) 0.90 (0.83–0.96) 0.89 (0.83–0.96)
PC ae C36:3 (quintiles)a
1 367/325 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
2 363/323 0.99 (0.80–1.23) 1.01 (0.82–1.25) 1.02 (0.82–1.26) 1.02 (0.82–1.26)
3 357/326 0.96 (0.77–1.19) 0.98 (0.79–1.22) 0.98 (0.79–1.22) 0.97 (0.78–1.21)
4 264/326 0.70 (0.56–0.88) 0.73 (0.58–0.91) 0.73 (0.58–0.91) 0.72 (0.58–0.91)
5 273/324 0.73 (0.58–0.91) 0.77 (0.61–0.96) 0.76 (0.61–0.96) 0.75 (0.60–0.95)
P trendb 0.0003 0.0020 0.0016 0.0010
CI confidence interval, HC hip circumference, OR odds ratio, SD standard deviation, WC waist circumference
aQuintile cut-points were determined on control participants
For log-transformed C2, cut-points were as follows, in log(μmol/L): < 1.18/1.18–1.37/1.37–1.55/1.55–1.77/≥ 1.77. For log-transformed PC ae C36:3, cut-points were
as follows, in log(μmol/L): < 1.81/1.81–1.94/1.94–2.04/2.04–2.16/≥ 2.16
bFor test of linear trends across quintiles, participants were assigned the median value in each category and the corresponding variable was modeled as a
continuous term
cConditional logistic regression conditioned on matching factors
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A
B
Fig. 2 Associations between C2 (a) and PC ae C36:3 (b) and breast cancer, by selected variables. CI: confidence interval; ER: estrogen receptor;
HER2: human epidermal growth factor receptor 2; PC: phosphatidylcholine; PR: progesterone receptor; SM: sphingomyelin. Odds ratios (ORs) are
estimated per standard deviation (SD) increase in log-transformed metabolite concentrations, from logistic regression conditioned on matching
variables. Homogeneity was tested by adding an interaction term in the conditional logistic regression model for menopausal status, use of
hormones at blood collection, fasting status, breast cancer subtype, and age at diagnosis (all matching factors or case characteristics). For waist
circumference (non-matching factor), logistic regression adjusted for each matching factor was used
His et al. BMC Medicine          (2019) 17:178 Page 9 of 13
observed a reduction in anti-tumor immune responses
in the context of arginine depletion in breast cancer,
suggesting a link between arginine and immunity. In
addition, higher plasma concentrations of arginine were
correlated with lower estradiol and insulin-like growth
factor 1 concentrations in premenopausal women [43],
linking arginine to known mechanisms leading to breast
cancer development. Regarding asparagine, a recent ani-
mal and in vitro study suggested that reduced asparagine
bioavailability resulted in slower disease progression
[44]. However, the role of asparagine in cancer develop-
ment is not clear.
Prospective data on metabolomics and risk of breast
cancer are limited [14, 16–18], and differences in ap-
proaches (targeted or untargeted metabolomics), analytical
methods (NMR or MS), and samples (serum or plasma)
make comparisons of the results difficult. Only one previ-
ous analysis used a similar targeted metabolomics ap-
proach with measurement of the same metabolites [14]
and showed that lysophosphatidylcholine a C18:0 was in-
versely associated with risk of breast cancer after Bonfer-
roni correction of P values, and that an inverse association
close to statistical significance was observed for PC ae
C38:1. However, none of the metabolites identified in the
present work were associated with risk of breast cancer in
this previous study, which did not investigate heterogen-
eity by use of hormones.
In a previous study applying NMR-based metabolomics
analyses in the SU.VI.MAX cohort [16], several amino
acids, lipoproteins, lipids, and glycerol-derived compounds
were identified as significantly associated to breast cancer
risk, suggesting that modifications in amino acid metabol-
ism and energetic homeostasis in the context of setting up
of insulin resistance could play a role in the disease. Re-
sults from the Prostate, Lung, Colorectal, and Ovarian
Cancer Screening (PLCO) study, based on an MS-based
metabolomics approach in serum samples, indicated that
some metabolites correlated with alcohol intake (androgen
pathway metabolites, vitamin E, and animal fats) [18], and
with BMI (metabolites involved in steroid hormones me-
tabolism and branched-chain amino acids) [17], were also
associated with breast cancer risk.
Heterogeneity by subtype was investigated only in the
PLCO study, showing that some metabolites (allo-isoleu-
cine, 2-methylbutyrylcarnitine [17], etiocholanolone glu-
curonide, 2-hydroxy-3-mthylvalerate, pyroglutamine, 5α-
androstan-3β, 17β-diol disulfate [18]) were associated
with risk of ER+ breast cancer, but not with breast can-
cer overall, indicating that the etiology of breast cancer
differs by subtype. In our work, however, we did not ob-
serve any heterogeneity of results according to receptor
status of the cancers.
This study is the largest prospective investigation of
metabolomics and risk of breast cancer to date. Strengths
of this work include its large sample size, which allowed
us to examine associations by breast cancer subtype. In
addition, the exclusion of cases diagnosed less than 2 years
after blood collection reduces the risk of reverse causation
Fig. 3 Adjusted P values for associations between metabolites and breast cancer, hormone non-users (1124 cases, 1124 controls). PC:
phosphatidylcholine; SM: sphingomyelin. Odds ratios (ORs) are estimated per standard deviation (SD) increase in log-transformed metabolite
concentrations, from logistic regression conditioned on matching variables. Raw P values were adjusted by permutation-based stepdown minP
(see “Methods” section for details); adjusted P values above 0.05 (dotted line) were considered statistically significant after correction for
multiple tests
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in our findings. Finally, the assessment of numerous life-
style factors and anthropometric measures allowed us to
examine and control for potential confounding.
A potential limitation to our work is that blood was
collected from participants at one time point only.
Nevertheless, the reliability of plasma metabolites ana-
lyzed here has been shown to be relatively stable over 4
months to 2 years, leading to the conclusion that a single
measurement might be sufficient [45, 46, 47]. In
addition, although fasting samples might be preferable
over non-fasting samples, in our study, cases and con-
trols were matched on fasting status and the results did
not differ by fasting state. Another limitation is that the
technologies that were used for some of the metabolites
(such as PCs and lysoPCs) do not allow for a precise
identification of the compounds measured, since the sig-
nal observed is not specific and may correspond to sev-
eral compounds. Lastly, it is important to note that the
aim of the present work was to screen metabolites asso-
ciated with risk, but that further work is needed to iden-
tify the factors that influence biological levels of the
metabolites associated with risk and to understand their
biological connection with breast cancer development.
Future studies should also integrate other molecular
markers known to be linked to breast cancer to gain
insight into biological mechanisms.
Conclusions
We observed a positive association between acetylcarnitine
(C2) and risk of breast cancer, and an inverse association
between PC ae C36:3 and risk of breast cancer. These asso-
ciations were limited to women not using hormones, as
were inverse associations with arginine, asparagine, PCs aa
C36:3, ae C34:2, ae C36:2, and ae C38:2. These metabolites
might be biomarkers of future breast cancer development.
These results need to be replicated in other epidemiological
studies, and more research is needed to identify determi-
nants of these metabolites.
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